Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03276923 · ClinicalTrials.gov registry record
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
A clinical trial of Rheumatoid Arthritis and Pregnancy Related, sponsored by Duke University.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03276923: Recruiting study of Rheumatoid Arthritis and Pregnancy Related, sponsored by Duke University.
NCT03276923 is a study of Rheumatoid Arthritis and Pregnancy Related that is actively recruiting participants, run by Duke University. The registered enrollment target is 1,000 participants, below the 4,686-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03276923, a study of Rheumatoid Arthritis and Pregnancy Related, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases. The main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy. Prior studies demonstrate the importance of increase inflammation prior to and during pregnancy on these outcomes. The future research will seek to better define these risk factors and to identify ways to may improve them.
Primary Outcome
The investigators will ask the participants questions from the MADRA-DAP questionnaire to determine poor pregnancy outcomes.
Conditions Studied
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2027-01-01 |
What NCT03276923 shows while recruiting
NCT03276923 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 4,686-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (79% lower).
The record links to 7 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 0 interventions.
NCT03276923 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03276923 about?
NCT03276923 is a clinical study titled "Maternal Autoimmune Disease Research Alliance (MADRA) Registry". This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases. The main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy. Prior studies demonstrate the importanc...
What is the current status of trial NCT03276923?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2018-01-01. Estimated completion is 2027-01-01.
What conditions does trial NCT03276923 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Pregnancy Related, Systemic Lupus Erythematosus, Autoimmune Diseases, Scleroderma.
Who is sponsoring clinical trial NCT03276923?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03276923 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03276923's enrollment target sits among peer trials
1,000 23rd of 197 higher than 175 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI